We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Intermolecular Inc | NASDAQ:IMI | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.195 | 1.19 | 1.20 | 0 | 01:00:00 |
From Apr 2019 to Apr 2024
By Anthony Shevlin
Merck KGaA (MRK.XE) said Thursday that Intermolecular Inc. (IMI) stockholders have approved the acquisition by the German company.
The transaction is expected to close in the second half, Merck said.
The pharmaceutical company agreed to acquire Intermolecular in May through a subsidiary for $1.20 per share in an all-cash transaction, which represented an equity value of around $62 million.
Merck will acquire Intermolecular through its subsidiary EMD Group Holding II, Inc.
Write to Anthony Shevlin at anthony.shevlin@dowjones.com; @anthony_shevlin
(END) Dow Jones Newswires
July 18, 2019 04:25 ET (08:25 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Intermolecular Chart |
1 Month Intermolecular Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
